Hepatic glucose overproduction is a major characteristic of type 2 diabetes. Since glucagon is a key regulator for glucose homeostasis, antagonizing the glucagon receptor (GCGR) is a possible therapeutic strategy for the treatment of diabetes mellitus. To study the effect of hepatic GCGR inhibition on the regulation of lipid metabolism, we generated siRNA-mediated GCGR knockdown (si-GCGR) in the db/db mouse. The hepatic knockdown of GCGR markedly reduced plasma glucose levels; however, total plasma cholesterol was increased. The detailed lipid analysis showed an increase in the low-density lipoprotein fraction, and no change in verylow-density and high-density lipoprotein fractions. Further studies showed that the increase in low-density lipoprotein was the result from over-expression of hepatic lipogenic genes and elevated de novo lipid synthesis. Inhibition of hepatic glucagon signaling via siRNA-mediated GCGR knockdown had an effect on both glucose and lipid metabolism in db/db mice.
Introduction
Glucagon is a counterregulatory hormone of insulin that has an important physiological role regulating glucose metabolism and preventing hypoglycemia in both animals and humans. The primary target organ of glucagon is liver. Hepatic glucagon receptor and glucagon interaction increases hepatic glucose production by activating glycogenolysis and gluconeogenesis, and abnormal glucagon signaling is associated with hyperglycemia in patients with type 2 diabetes (1). Several preclinical and clinical studies have demonstrated the utility of inhibiting glucagon signaling as one potential strategy for the treatment of type 2 diabetes. For example, pharmacologic or antisense oligonucleotide (ASO) interventions that suppress glucagon receptor signaling have been shown to reverse hyperglycemia in animal models (2) (3) (4) (5) (6) (7) . Genetic interventions using complete Gcgr knock-out mice also lowered fasting and fed glucose levels with increased GLP-1 and glucagon levels (8) (9) (10) . More importantly, intervention with glucagon receptor antagonists revealed an impressive circulating plasma glucose-lowering effect in humans (11;12).
However, concerns over the association between glucagon receptor signaling inhibition and dyslipidemia, specifically increased low-density lipoprotein cholesterol (LDL-C) levels from Gcgr knock-out mice and clinical data using a glucagon receptor antagonist, have been raised (8;12) . Although most studies of glucagon receptor signaling inhibition showed robust glucose lowering, the effects on lipids and the mechanisms linking hepatic glucagon action to LDL-C levels have not been elucidated. The dyslipidemia associated with type 2 diabetes typically involves increased triglycerides (TG), reduced high-density lipoprotein cholesterol (HDL-C) levels, and increased cardiovascular risk (13) . Cardiovascular risk is further increased when type 2 diabetes is complicated by elevated LDL-C levels. Thus, it is important to evaluate the impact of hepatic glucagon action inhibition on lipid metabolism, especially hepatic lipid synthesis, TG secretion, and levels of LDL-C and HDL-C. The objective of the present study by guest, on www.jlr.org Downloaded from
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Massachusetts, USA), respectively, according to the manufacturer's instructions. Glucagon was measured using commercial ELISA kits (Linco Research Immunoassay, St. Charles, Missouri, USA). Non-esterified fatty acids (NEFA) was measured using commercially available enzymecoupled spectrophotometric assays (Wako Chemicals Inc. USA), and beta hydroxybutylate (bHB) was measured using Liquid Enzymatic Reagent Kit (Stanbio Laboratory, Boerne, Texas, USA). Plasma apolipoprotein (apo) B and apoA1 levels were measured by liquid chromatography/mass spectrometry (LC/MS) assay, and protein convertase subtilisin/kexin type 9 (PCSK9) was measured using murine-specific ELISA, as previously described (14;15). All assays were performed following the recommended procedures for instrument operation, calibration, quality control, and assay guidelines. Hepatic TG and cholesterol content were measured as previously described (16) .
Western blot analysis
To examine expression of proteins, liver samples were collected and cell lysates were prepared as described previously (16) . Western blot analysis was carried out as described earlier (16) using anti-Ldlr antibody (Abcam, PLC, Waltham, Massachusetts, USA) and anti-α Tubulin (Abcam, PLC).
Lipoprotein separation and TG production
The major lipoproteins, very low-density lipoprotein cholesterol (VLDL; d<1.006 g/ml), LDL-C (d=1.006-1.063 g/ml), and HDL-C (d=1.063-1.21 g/ml) were isolated by sequential density ultracentrifugation of plasma using a TLA-100 rotor (Beckman Coulter, Inc., Brea, California, USA), following procedures described previously (16) . Sodium bromide (NaBr) (Sigma-Aldrich, St. Louis, Missouri, USA) was used to prepare the density solution. ApoB-containing lipoproteins were run on SDS-PAGE gels and visualized by 0.05% Coomassie blue staining (Sigma-Aldrich). P407 (Pluronic F-127, Invitrogen, Grand Island, New York, USA) was used in by guest, on www.jlr.org Downloaded from 6 mice to measure TG production rate in plasma. Mice were fasted overnight and injected with P407 (10 ml/kg body weight). Blood samples were collected at 0, 1, 2, 4 and 6 hours after injection, and TG levels were quantified, as described above.
Fast protein liquid chromatography (FPLC)
Lipoproteins were fractionated by FPLC gel filtration using a Superose-6 size exclusion column (GE Healthcare LifeSciences, Inc., Piscataway, New Jersey, USA) attached to a Dionex highperformance liquid chromatography (HPLC) system (Thermo Fisher Scientific Inc). The column effluent was mixed with a commercially available enzymatic reagent for cholesterol (Wako Chemicals USA), and levels were continuously measured using a photodiode array detector at 600 nm absorbance. The first, second, and third peaks were attributed to VLDL, LDL-C, and HDL-C, respectively, and the area under each peak was calculated using Chromeleon software, as previously described (17) .
Real-time quantitative PCR analysis
Liver samples were homogenized, and total RNA was isolated using RNA easy (Qiagen, Inc., Valencia, California, USA), according to the manufacturer's instructions. Two µg total RNA from each sample was reverse transcribed with cDNA kit (Life Technologies Corp, Carlsbad, California, USA), and mRNA expression for the genes of interest were measured by real-time quantitative polymerase chain reaction (PCR) with SYBR Green PCR core reagents and primers (Qiagen, Inc), as previously described (18) . The relative amounts of specific target amplicons for each primer set were estimated by a cycle threshold (Ct) value and were normalized to the copy number of housekeeping genes (18) . The P-values were determined by two-tailed equal variance Student's t-test, comparing the ∆Ct values of the si-Control and siGCGRgroups. 
GC-quadrupole-MS analyses of palmitate and cholesterol synthesis
At day 11 after siRNA injection, 
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Values are expressed as means ± SEM. The statistical significance of the differences was determined by Student's t test, and a P value <0.05 was considered significant.
Results

Hepatic GCGR knockdown lowered plasma glucose levels
Eleven days after siRNA injection, a reduction in hepatic Gcgr mRNA expression (61%) in si-GCGR mice was observed (Fig. 1A) . There was no difference in cumulative body weight in the si-GCGR si-GCGRsi-GCGRgroup compared with the control group throughout the study (Fig.   1B) . Compared with si-control mice, both ambient and fasting glucose levels in si-GCGRsi-GCGR-treated mice were reduced at day 4, and the reduction was sustained to day 11 after treatment (Figs. 1C, D) . Although plasma glucagon levels were elevated in the si-GCGRsi-GCGR-treated mice, plasma insulin levels were similar in the two groups (Figs. 1E, F) .
The effect of hepatic GCGR knockdown on plasma lipid levels
Lipoprotein analysis showed a 2-fold increase of LDL-C levels in si-GCGRsi-GCGR-treated mice compared to those in the si-control group, with no significant difference in VLDL and HDL-C levels ( Fig. 2A) . In addition, there were no differences in hepatic LDL receptor expression, plasma PCSK9 levels, or lipoprotein lipase activity between these two groups (Figs. 2B, C; Supplementary Fig. 1A ). The use of ultracentrifugation to isolate lipoprotein fractions revealed a slight increase in apoB100 content in LDL fractions, with a tendency toward increased total plasma apoB levels in si-GCGRsi-GCGR mice (Figs. 2D, E) . FPLC separation confirmed an increase of LDL-C fraction in si-GCGRsi-GCGR mice (Fig. 2F) .
Hepatic GCGR knockdown mice showed increased hepatic lipid contents and lipogenic gene expression by guest, on November 9, 2017 www.jlr.org
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There were increased levels of TGs and cholesterol in the liver samples from si-GCGR mice (Fig. 3A) . This increase may have potentially resulted from increased expression of hepatic lipogenic genes. There was no differential expression of sterol regulatory element-binding protein isoform-1c (Srebf1) or SREBP-2 (Srebf2)mRNA in fed liver samples from si-GCGR mice compared with controls (Fig. 3B) . However, we observed a profound increase in the expression of genes in SREBP pathways, such as fatty acid synthase (Fasn), acetyl-CoA carboxylase A and B (Acaca, Acacb), stearoyl-CoA desaturase (Scd1), elongation of very long-chain fatty acids protein (Elovl5, Elovl6), long-chain-fatty acid-CoA ligase (Acsl3, Acsl5), Acyl-CoA synthetase short-chain family member 2 (Acss2), ATP citrate lyase (Acly), acetoacetyl-CoA synthetase (Aacs), mevalonate decarboxylase (Mvd), and farnesyl diphosphate synthetase (Fdps) (Fig. 3B) . 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr) showed tendency of increased expression while MLX interactor (Chrebp) mRNA expression was unchanged (Fig.   3B ). Microsomal triglyceride transfer protein (Mttp) showed a moderately increase in expression, whereas other potential candidate molecules involved in the regulation of apoBcontaining lipoprotein levels, including apoB, Lpl, PCSK9, or Ldlr mRNA expression, were unchanged (Fig. 3B) . As expected with inhibition of glucagon signaling, the expression of glucokinase (Gck) and pyruvate kinase (Pklr) were increased and the expression of phosphoenolpyruvate carboxykinase (Pepck) was decreased in the hepatic Gcgr knockdown mice group (Fig. 3B) . Upregulation of lipogenic and glycogen biosynthetic genes and reduction of gluconeogenic gene expression were observed with hepatic Gcgr knockdown. These findings suggest that reduced levels of hepatic glucagon receptor in db/db mice produces an upregulation of lipogenic genes, which may eventually lead to increased hepatic lipid contents. (Figs. 4A, B) . Presumably, changes in the production of these plasma lipids reflect hepatic metabolism since the liver is a major source of newly made circulating lipids. To determine whether these changes lead to altered hepatic lipoprotein secretion, the lipase inhibitor P407 was administered by injection to both groups of mice. P407 blocks the clearance of apoB-containing lipoproteins from the circulation, thus, the rate of accumulation of lipoprotein reflects the secretion rate in plasma. The results showed an increase in hepatic secretion of TGs in si-GCGR mice as well as increased basal plasma TG levels (Figs. 4C,D) . Compared to control groups there was no difference of plasma levels of NEFA, bHB, alanine transaminase, and aspartate aminotransferase in si-GCGR group (Figs.   4E, F;Supplementary Fig. 1B ).
Discussion
Targeting glucagon action to treat type 2 diabetes has been of great interest. This study demonstrated a strong and sustained effect on glucose lowering in siRNA-mediated hepatic studies have also illustrated the potential hypolipidemic actions of glucagon, specifically, with respect to reduced plasma TG, VLDL secretion, hepatic TG contents, cholesterol levels, and increased fatty acid oxidation (22) (23) (24) (25) . These findings underscore the importance of understanding the potential implications of down-regulating glucagon signaling on lipid metabolism.
Previously published studies examining GCGR inhibition revealed somewhat inconsistent results with respect to lipid effects insofar as not all Gcgr -/-mice or GCGR ASOtreated mice exhibited dyslipidemic phenotypes (5;6;8;9;23). In some studies, Gcgr -/-mice showed increased plasma LDL or total cholesterol levels, but no increased (or even reduced)
plasma TG levels (8;9). In another study, Gcgr -/-mice showed increased TG secretion and increased plasma TG levels after a 16-hour fast (23) . GCGR ASO-treated db/db mice showed reduced plasma TG levels and increased hepatic TG contents (5;6).
In the current study, inhibition of GCGR by si-RNA demonstrated effects on both glucose and lipid metabolism in the db/db mouse model. The si-GCGR db/db mouse showed robust glucose lowering and increased LDL-C levels. Si-GCGR mice showed increased hepatic lipid contents, lipogenic gene expression, and TG production. All of these aggravated dyslipidemic characteristics are associated with an up-regulation of de novo lipogenesis. We did not observe any increase in plasma NEFA concentrations to suggest increased fatty acid flux to liver, nor the reduction in beta-hydroxybutyrate levels and/or reduction in the expression of fatty acid oxidation genes in si-GCGR mice (Figs. 4E, F, data not shown) . Hepatic LDLR protein or plasma PCSK9 levels also were unchanged; therefore, the increasing LDL-C is less likely due to the reduction in LDL fractional catabolism. Based on our results, we propose that the elevated rate of lipogenesis is a major driving force for the observed increases in LDL-C levels and increased TG production in si-GCGR db/db mice. Interestingly, siRNA-mediated knock down of fructose-1,6-bisphosphatase 1, which converts fructose 1,6 biphosphate to fructose 6-phosphate in gluconeogenesis, also reduced plasma glucose levels, increased LDL-C levels Fig 2. , data not shown).
We also tested effect of knockdown glucagon receptor in a mouse model without impairment of leptin signaling, CETP transgenic LDLR +/-mouse, using siRNA targeting Gcgr.
The si-GCGR treated mice showed ~20% reduction in plasma glucose and ~24% induction of LDL-C levels in CETP transgenic LDLR +/-mouse model (Supplementary Fig 3) .
The inhibition of hepatic gluconeogenesis and possible increase in glycolysis in si-GCGR mice could lead to build-up of acetyl-CoA, which can be used as carbon substrate for lipid synthesis. The newly synthesized hepatic lipid can be either stored or secreted as VLDL.
Certainly, we observed increased hepatic lipid contents as well as increased TG production.
Another explanation could be that knocking down GCGR sensitized the liver to insulin-mediated lipogenesis. It is well documented that insulin upregulates fatty acid biosynthesis and glycolysis genes. One study showed inhibitory effects of glucagon on hepatic lipogenesis by antagonizing the signaling pathway mediated by insulin (26) . A recent study showed a global upregulation of lipid biosynthesis and glycolysis genes in Gcgr -/-mice liver at both mRNA and protein levels (27) . Importantly, Gcgr knockout or Gcgr monoclonal antibody-treated preclinical animal models showed elevated plasma cholesterol and LDL cholesterol (8;28), which might be caused by increased hepatic cholesterol synthesis. Indeed, our stable isotope tracer studies demonstrated that cholesterol synthesis ( 2 H-labeling of cholesterol) was significantly increased in si-GCGR treated mice. It is interesting to note that we did not observe robust change of gene expressions involved in cholesterol synthesis, which is somewhat inconsistent with the report that multiple genes of cholesterol biosynthesis were elevated in Gcgr -/-mice (27) . This discrepancy might be due to differences in the genetic background, the dysmetabolic status of mice, and the degree of GCGR deficiency. The implications of these findings could be that glucagon/GCGR signaling not only plays a role in glucose metabolism but also protects against excessive hepatic lipid production.
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Given that increased atherosclerosis is a major cause of morbidity and mortality in type 2 diabetes and metabolic syndrome ( glucagon (E), and insulin levels (F) measured in si-Control and si-GCGR mice plasma samples.
Values are expressed as means ± SEM (n=7-8). The statistical significance of the differences was determined by Student's t test, and a P value <0.05 was considered significant (*P<0.05; **<0.01 vs. si-control). Hepatic triglyceride (TG) and cholesterol levels in the livers of si-Control and si-GCGR mice (A).
Data are shown as the mean ± SEM (n=8). The statistical significance of the differences was determined by Student's t test, and a P value <0.05 was considered significant (*P<0.05; **<0.01 vs. si-control). Analysis of hepatic gene expression by real time quantitative PCR in siControl and si-GCGR mice (n=8) (B). Fold regulation indicates the ratio of expression levels in si-GCGR over si-Control. Livers were collected from mice on fed condition. The statistical significance of the differences was determined by Student's t test, and a P value <0.05 was considered significant. significance of the differences was determined by Student's t test, and a P value <0.05 was considered significant (*P<0.05; **<0.01 vs. si-control).
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